

Structure-Activity Relationships of New Taxoids Derived from 14 β -Hydroxy-10-deacetylbaecatin III

Iwao Ojima,*† Young Hoon Park,† Chung-Ming Sun,† Ivana Fenoglio,† Giovanni Appendino,‡ Paula Pera,§ and Ralph J. Bernacki*§

Department of Chemistry, State University of New York at Stony Brook, Stony Brook, New York 11794-3400, Dipartimento di Scienza e Tecnologia del Farmaco, Università di Torino, 10125 Torino, Italy, and Department of Experimental Therapeutics, Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263

Received December 10, 1993

Taxol (paclitaxel), a complex diterpene isolated from the bark of the western yew (*Taxus brevifolia*), is currently considered the most exciting lead in cancer chemotherapy.¹⁻³ Taxotere (docetaxel), a semisynthetic analog, also has shown great promise.⁴ Paclitaxel and docetaxel possess high cytotoxicity and strong antitumor activity against different cancers which have not been effectively treated by existing antitumor drugs.^{5,6} Paclitaxel was approved by FDA in late 1992 for the treatment of advanced ovarian cancer and is currently in phase II and III clinical trials for breast cancer and lung cancers.² Docetaxel is currently in phase II and III clinical trials in United States, Europe, and Japan.⁶

A recent report on clinical trials of paclitaxel and docetaxel, however, has disclosed that these highly effective drugs have a number of undesired side effects as well as multidrug resistance (MDR).^{1,5,7} Therefore, it is very important to develop new anticancer drugs which have less undesirable side effects, better pharmacological properties, and/or activity spectra against various tumor types different from those of these two drugs.

Recently, a novel taxane diterpenoid, 14 β -hydroxy-10-deacetylbaecatin III (14 β -OH-DAB), was isolated from the needles of *Taxus wallichiana* Zucc. and other plant parts.⁸ Because of an extra hydroxyl group at the C-14 position, 14 β -OH-DAB has proven to possess much higher water solubility than the usual 10-deacetylbaecatin III (DAB), which is currently used for the practical production of paclitaxel and docetaxel as mentioned above. Therefore, the new antitumor taxanes derived from 14 β -OH-DAB can be expected to have substantially improved water solubility, bioavailability, and hydrophobicity-related drug resistance.⁷ These improved pharmacological properties may well be related to the modification of undesirable toxicity and activity spectra against different cancer types.

Syntheses of New Taxoids. A series of new taxoids were synthesized from 14 β -OH-DAB using a highly efficient and practical coupling protocol based on the β -lactam synthon method developed in our laboratory.⁹⁻¹¹ Thus, the C-13 side chain precursors, (3R,4S)-1-acyl-3-(EEO)-4-phenylazetid-2-ones 1 (EE = ethoxyethyl) with extremely high enantiomeric purity, were obtained through our efficient chiral ester enolate-imine cyclocondensation method^{10,11} in four steps in 78-80% overall yields. The 7,10-DiTroc-14 β -OH-DAB (**3**) (Troc = 2,2,2-trichloroethoxycarbonyl) were prepared by reacting with 4 equiv

of Troc-Cl in pyridine at 80 °C for 5 min in 55% yield (Scheme 1). In a similar manner, 7,10-diTroc-14 β -OH-DAB-1,14-carbonate (**2**) was obtained in 75% yield by reacting 14 β -OH-DAB with 6 equiv of Troc-Cl in pyridine at 80 °C for 5 min (Scheme 1).

The reaction of **3** with β -lactam **1a** (1.2 equiv) was carried out in the presence of 1.2 equiv of NaHMDS at -40 °C for 30 min to give 7,10-ditroc-2'-EE-14-hydroxydocetaxel-1,14-carbonate (**4a**) in 86% yield (Scheme 2). The coupling product **4a** was deprotected under modified Commerçon conditions¹² by treating with activated Zn in acetic acid and methanol at 40 °C for 9 h to give 14-hydroxydocetaxel-1,14-carbonate (**5a**) in 70% yield (Scheme 2).¹³ 14 β -Hydroxypaclitaxel-1,14-carbonate (**5b**) was obtained in the same manner through the coupling of **2** with β -lactam **1b** (1.2 equiv) (89% yield) followed by deprotection (70% yield) (Scheme 2).¹³

The coupling of **3** with β -lactam **1a** and subsequent deprotection were performed under similar conditions to give *pseudo*-docetaxel (**7a**) in 50% overall yield (Scheme 3).¹³ In the same manner, 10-deacetyl-*pseudo*-paclitaxel (**7b**) was synthesized through the coupling of β -lactam **1b** with **3**, followed by deprotection in 52% overall yield (Scheme 3).¹³

Cytotoxicity Assay. Cytotoxicities of these new taxanes **5a,b** and **7a,b** were evaluated *in vitro* against human cancer cell lines. As shown in Table 1, these new taxanes possess strong cytotoxicities against human breast, non-small cell lung, ovarian, and colon cancer cells, and especially, **5a** exhibits activity better than that of paclitaxel for non-small cell lung cancer (A549) and colon cancer (HT-29) cell lines. This agent also shows substantial activity against an adriamycin-resistant breast cancer (MCF7-R) cell line. Attachment of an *N*-acylphenyl-isoserine side chain at C-14 instead of the original C-13 position results in a ca. 10-fold decrease in cytotoxicity. However, **7a** still retains 10 nM level (IC₅₀) cytotoxicities against human cancer cells. This observation might provide us with a very important clue for understanding of the active conformation of paclitaxel series anticancer taxanes. For instance, the molecular modeling of **7a**, starting from the X-ray structure of docetaxel,¹⁵ using SYBYL 6.0 program (Figure 1) reveals an unexpected excellent overlap of the energy-minimized structure of **7a** with that of docetaxel in which the two hydrophobic substituents, i.e., phenyl at C-3' and *tert*-butoxy group, have exchanged their positions almost perfectly. This implies that the *pseudo*-taxoid **7a** can mimic, to some extent, the binding conformation of docetaxel to the tubulin receptor although the identification of the "active conformation" of paclitaxel and docetaxel should await further investigation.

The microtubule disassembly inhibitory activities of these new taxoids were also examined. The activities relative to paclitaxel are as follows (*T* = IC₅₀ of paclitaxel): **5a**, 0.9*T*; **5b**, 3*T*; **7a**, >50*T*; **7b**, >100*T*.


The *in vivo* antitumor activity of **5a** has been evaluated against A151 human ovarian carcinoma xenograft in nude athymic mice, which shows an equivalent or slightly better activity than paclitaxel, causing total regression of the tumor. The results of the *in vivo* antitumor activities of these new taxoids will be reported elsewhere in the near future. Further investigations on the SAR of new taxoids derived from 14 β -OH-DAB are actively under way.

* State University of New York at Stony Brook.


† Univesità di Torino.

§ Roswell Park Cancer Institute.


Scheme 1



Scheme 2




Scheme 3

Table 1. Cytotoxicities of New Taxanes (IC₅₀, nM)^a

cell line	paclitaxel	5a	5b	7a	7b
A121 (ovarian)	6.1 ± 2.4	6.2 ± 0.4	105	80	1044
A549 (NSCL)	3.6 ± 1.1	2.1 ± 0.7	33	31	512
HT-29 (colon)	3.2 ± 0.6	1.8 ± 0.7	24	50	248
MCF7 (breast)	1.7 ± 0.4	1.8 ± 0.8	11	26	269
MCF-7-R (breast)	299 ± 97	543 ± 145	>1000	>1000	>1000

^a The concentration of compound which inhibit 50% (IC₅₀) of the growth of human tumor cell line, A121 (ovarian carcinoma), A549 (non-small cell lung carcinoma), HT-29 (colon carcinoma), MCF7 (mammary carcinoma), or MCF7-R (mammary carcinoma cells 180-fold resistant to adriamycin), after 72 h drug exposure according to the method developed by Skehan et al.¹⁴ The data represent the mean values of at least three separate experiments.

Figure 1. Chem 3D representation of *pseudo*-docetaxel (7a) and docetaxel.

Acknowledgment. This research was supported by grants from the National Institutes of Health (GM427980), the Center for Biotechnology at Stony Brook which is sponsored by the New York State Science & Technology Foundation, and the National Cancer Institute (CA13038). Generous support from Indena, SpA, is also gratefully acknowledged. The authors are grateful to Dr. Ezio Bombardelli, Indena, SpA for providing us with 14-hydroxybaccatin III and for helpful discussions. They

would like to thank Dr. Daniel Guénard, Institut de Chimie des Substance Naturelles, CNRS, Gif-sur-Yvette, for microtubule disassembly assay. One of the authors (I.F.) is grateful to Università di Torino for a postdoctoral fellowship.

Supplementary Material Available: General experimental procedures for the syntheses of 5a, 5b, 7a, and 7b from 14-hydroxybaccatin III and the characterization data for new taxoids (7 pages). Ordering information is given on any current masthead page.

References

- Rowinsky, E. K.; Onetto, N.; Canetta, R. M.; Arbuck, S. G. Taxol: The First of the Taxanes, and Important New Class of Antitumor Agents. *Seminars Oncol.* **1992**, *19*, 646-662.
- Suffness, M. Taxol: From Discovery to Therapeutic Use. In *Annual Reports in Medicinal Chemistry*; Bristol, J. A., Ed.; Academic Press: San Diego, 1993; Vol. 28, Chapter 32, pp 305-314.
- Kingston, D. G. I. The Chemistry of Taxol. *Pharmacol. Ther.* **1991**, *52*, 1-34 and references cited therein.
- Guénard, D.; Guéritte-Vogelein, F.; Potier, P. Taxol and Taxotere: Discovery, Chemistry, and Structure-Activity Relationships. *Acc. Chem. Res.* **1993**, *26*, 160-167.
- Seidman, A. D. Clinical Results of Taxol in the Treatment of Advanced Breast Cancer: Single Agent Trials; Stony Brook Symposium on Taxol and Taxotère, May 14-15, 1993, Stony Brook, NY, Abstracts pp 14-16.
- Ravdin, P. M. Taxotere, A Promising New Agent For the Treatment of Metastatic Breast Cancer; Stony Brook Symposium on Taxol and Taxotère, May 14-15, 1993, Stony Brook, NY, Abstracts p 18.
- Horwitz, S. B. Taxol: Mechanism of Action and Resistance; Stony Brook Symposium on Taxol and Taxotère, May 14-15, 1993, Stony Brook, NY, Abstracts pp 23-24.
- Appendino, G.; Gariboldi, P.; Gabetta, B.; Pace, R.; Bombardelli, E.; Viterbo, D. 14β-Hydroxy-10-deacetyl baccatin III, a New Taxane from Himalayan Yew (*Taxus Wallichiana* Zucc.). *J. Chem. Soc., Perkin Trans. 1* **1992**, 2925-2929.
- Ojima, I.; Habus, I.; Zhao, M.; Georg, G. I.; Jayasinghe, R. Efficient and Practical Asymmetric Synthesis of the Taxol C-13 Side Chain, *N*-Benzoyl-(2*R*,3*S*)-3-phenylisoserine, and Its Analogs via Chiral 3-Hydroxyl-4-aryl-β-lactams Through Chiral Ester Enolate-Imine Cyclocondensation. *J. Org. Chem.* **1991**, *56*, 1681-1684.
- Ojima, I.; Habus, I.; Zhao, M.; Zucco, M.; Park, Y. H.; Sun, C. M.; Brigaud, T. *New and Efficient Approaches to the Semisynthesis of Taxol and Its C-13 Side Chain Analogs by Means of β-Lactam*

- Synthon Method. *Tetrahedron* 1992, 48, 6985. See also: (b) Holton, R. A. Method for Preparation of Taxol. Eur. Pat. Appl. EP 400-971, 1990. (c) Georg, G. I.; Cheruvallath, Z. S. Synthesis of Biologically Active Taxol Analogues with Modified Phenylisoserine Side Chains. *J. Med. Chem.* 1992, 35, 4230-4237.
- (11) Ojima, I.; Sun, C. M.; Zucco, M.; Park, Y. H.; Duclos, O.; Kuduk, S. D. A Highly Efficient Route to Taxotère by the β -Lactam Synthon Method. *Tetrahedron Lett.* 1993, 34, 4149-4152.
- (12) Commercon, A.; Bezard, D.; Bernard, F.; Bourzat, J. D. Improved Protection and Esterification of a Precursor of Taxotère and Taxol Side Chains. *Tetrahedron Lett.* 1992, 33, 5185.
- (13) 5a: mp 191-192 °C; $[\alpha]^{20}_D$ -22.83° (c 0.193, CHCl₃). 5b: mp 208 °C dec; $[\alpha]^{20}_D$ -19.0° (c, 0.50, CHCl₃). 7a: mp 152-153 °C; $[\alpha]^{20}_D$ +20.9° (c 0.67, CH₂Cl₂). 7b: mp 198-202 °C; $[\alpha]^{20}_D$ -13.2° (c 0.38, MeOH). For full identification data, see the supplementary material.
- (14) Skehan, P.; Streng, R.; Scudierok D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening. *J. Natl. Cancer Inst.* 1990, 82, 1107-1112.
- (15) Guéritte-Vogelein, F.; Guénard, D.; Mangatal, L.; Potier, P.; Guilhem, J.; Cesario, M.; Pascard, C. Structure of a Synthetic Taxol Precursor: *N*-*tert*-Butoxycarbonyl-10-deacetyl-*N*-debenzoyltaxol. *Acta Crystallogr.* 1990, C46, 781.